Focus: TwoStep Therapeutics is a pre-revenue biotech focused on peptide-drug conjugate (PIP) therapies for oncology, recently cleared for IND and backed by $62.5M Series A funding. The company is in early clinical stage with one Phase 1 program targeting non-small cell lung cancer.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Best fit for researchers, oncology specialists, or early-stage operators seeking equity upside and platform-building opportunity; avoid if seeking near-term job security or rapid internal mobility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for TwoStep Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from TwoStep Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
TwoStep gains series A backing and FDA clearance to trial multi-target cancer conjugate - The Pharma Letter
TwoStep gains series A backing and FDA clearance to trial multi-target cancer conjugate The Pharma Letter
TwoStep Therapeutics secures $62.5m funding to advance TS-104 - Pharmaceutical Technology
TwoStep Therapeutics secures $62.5m funding to advance TS-104 Pharmaceutical Technology
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate - Business Wire
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate Business Wire
5th Targeted Radiopharmaceuticals Summit US - San Diego Magazine
5th Targeted Radiopharmaceuticals Summit US San Diego Magazine
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo